1 January 2021 in Journal of Medicine and Life
Neuromuscular junction (NMJ) disorders include several dysfunctions that ultimately lead to muscle weakness. Myasthenia gravis (MG) is the most prevalent NMJ disorder with a highly polymorphic clinical presentation and many different faces. Being an autoimmune disease, MG correlates with the presence of detectable antibodies directed against the acetylcholine receptor, muscle-specific kinase, lipoprotein-related protein 4, agrin, titin, and ryanodine in the postsynaptic membrane at the NMJ. MG has become a prototype serving to understand both autoimmunity and the function of the NMJ better. The aim of this review is to synthesize some of the epidemiological data available. Epidemiological data regarding MG are important for postulating hypotheses regarding its etiology and facilitating the description of MG subtypes. Thus, adequate documentation through broad databases is essential. The incidence and prevalence of MG reported around the globe have been rising steadily and consistently over the past decades. Ethnic aspects, gender-related differences, and environmental risk factors have been described, implying that these might contribute to a specific phenotype, further suggesting that MG may be considered an umbrella term that covers several clinical entities.
5 March 2025 in BMJ Case Reports
Lambert–Eaton myasthenic syndrome (LEMS) is a rare neuromuscular junction (NMJ) disorder which is categorised as either paraneoplastic or primary autoimmune. In both forms, auto-antibodies target voltage-gated calcium channels at the presynaptic level of the NMJ. Paraneoplastic LEMS is most commonly associated with small cell lung cancer (SCLC), but it can also be caused by other malignancies. We report a rare case of paraneoplastic LEMS associated with oesophageal carcinoma. Over the course of a year, the patient presented with a range of unclear and evolving symptoms, leading to an initial diagnosis of Guillain-Barré syndrome and subsequently Myasthenia Gravis. The diagnosis of LEMS was confirmed serologically, after the discovery of oesophageal cancer, at a stage where treatment options were limited, leading to an unfavourable outcome. This case emphasises the importance of diagnosing LEMS before tumour detection, maintaining suspicion for LEMS in atypical presentations, and thoroughly investigating for malignancies, including extrapulmonary sites.
1 September 2021 in The Moldovan Medical Journal
Background: Multiple sclerosis (MS) is a disease that affects young people of reproductive age (20-40 years old), predominantly women. Therefore, almost every patient has questions about pregnancy and breastfeeding. Family planning is one of the key issues in the choice of treatment tactics. Despite the growing number of therapeutic options for individualized treatment, it is still a question how to manage women with MS who become pregnant while taking disease-modifying drugs or want to become pregnant after starting this treatment. Conclusions: Women with MS should not be discouraged from pregnancy due to their illness. It is necessary to proactively discuss pregnancy planning with all women with MS of childbearing age. Based on available data, interferon beta and glatiramer acetate appear to be most suitable for use up until the time of confirmed pregnancy. A large amount of data (more than 1000 cases) obtained from registries shows that use of interferon beta before conception and during pregnancy suggests no evidence of increase in the rate of congenital anomalies or spontaneous abortions. For women with persistent high disease activity, pulsed immune reconstitution therapy gives additional opportunity for family planning after the last dose. The choice between available options for pulsed immune reconstitution therapy should be based on efficacy balanced against the risks.